<DOC>
	<DOCNO>NCT02262455</DOCNO>
	<brief_summary>This Phase I study test safety , pharmacokinetics effectiveness STM 434 alone , combination liposomal doxorubicin , patient ovarian cancer advance solid tumor .</brief_summary>
	<brief_title>Effects STM 434 Alone Combination With Liposomal Doxorubicin Patients With Ovarian Cancer Other Advanced Solid Tumors</brief_title>
	<detailed_description>This open-label ( identity assign study drug know ) study evaluate safety , pharmacokinetics ( study body drug ) , pharmacodynamics ( study drug body ) , anti-tumor activity STM 434 ( inhibitor activin A ) patient ovarian cancer advance solid tumor . The study conduct 3 phase ( Part 1 , Part 2 Part 3 ) . In first part study ( Part 1 ) , enroll patient multiple solid tumor type , maximum tolerate dose ( MTD ) STM 434 determine use second third part study ( Parts 2 3 ) . In second part ( Part 2 ) , enroll patient ovarian cancer , STM 434 administer alone , third part ( Part 3 ) , enroll patient ovarian cancer , STM 434 give together chemotherapy call liposomal doxorubicin . Doses STM 434 ( start 0.25 mg/kg maximum 4 mg/kg ) take one three dose schedule determine MTD . Patients continue take STM 434 tumor progress . Serial blood sample collect pharmacokinetic pharmacodynamic test safety monitor throughout study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Males postmenopausal female , 18 year old Advanced solid tumor histologic diagnosis confirm cancer Patients recurrent metastatic locally advanced disease consider refractory intolerant standard treatment available tumor , tumor standard treatment available Subjects serous ovarian/fallopian tube/primary peritoneal , granulosa cell tumor clear cell tumor consider platinum refractory/resistant , define least one prior platinumbased chemotherapeutic regimen subsequent platinumfree interval &lt; 12 month , progression platinumbased therapy , persistent disease platinumbased therapy , eligible . Intolerant subject , define unable receive platinum due toxicity , eligible . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Informed consent History gastrointestinal bleeding within past 6 month History epistaxis require medical/surgical intervention ( nasal packing ) within past 6 month History central nervous system hemorrhage History bleeding diathesis know qualitative platelet defect ( include von Willebrand disease ) Ongoing need therapeutic anticoagulant ( full dose heparin , warfarin , factor Xa direct thrombin inhibitor ; rivaroxaban , apixaban , dabigatran ) chronic use aspirin antiplatelet agent ( ticlopidine clopidogrel ) History hereditary hemorrhagic telangiectasia ( HHT , OslerWeberRendu syndrome ) Myocardial infarction , unstable angina within past 6 month , congestive heart failure New York Heart Association Class II great Chemotherapy , hormonal therapy radiation therapy within past 3 week , antibody/biologic therapy within 5 halflives within past 4 week ( whichever longer ) Current bowel obstruction Brain metastasis Known HIV infection and/or active Hepatitis B C infection Prior treatment investigational product within past 4 week Not willing use contraception ( inclusive abstinence )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Serous tumor</keyword>
	<keyword>Granulosa tumor</keyword>
	<keyword>Clear Cell tumor</keyword>
	<keyword>Endometrial cancer</keyword>
	<keyword>Advanced solid tumor</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Head Neck cancer</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Small cell lung cancer</keyword>
	<keyword>Gastric cancer</keyword>
	<keyword>Kidney cancer</keyword>
	<keyword>Pancreatic cancer</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Colorectal cancer</keyword>
	<keyword>Bladder cancer</keyword>
	<keyword>Esophagus cancer</keyword>
	<keyword>Liver cancer</keyword>
	<keyword>Hepatobiliary cancer</keyword>
	<keyword>Skin cancer</keyword>
</DOC>